Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 591

Sort by

Sort Order Select

Journal Articles

How I manage acquired pure red cell aplasia in adults

Carmelo Gurnari, Jaroslaw P. Maciejewski

Blood (2021) 137 (15): 2001–2009.

https://doi.org/10.1182/blood.2021010898

Published: 2021

Journal Articles

Rare disease + lots of sequencing = mechanism?

Gary M. Kupfer

Blood (2021) 137 (14): 1849–1850.

https://doi.org/10.1182/blood.2020010384

Published: 2021

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia

Michael Andreeff, MD PhD, Jianfang Zeng, MD, Alice Soragni, PhD, Vivian Ruvolo, Bing Z Carter, PhD, Jo Ishizawa, MD PhD, Jared K. Burks, PhD, David Eisenberg, PhD

Blood (2019) 134 (Supplement_1): 3786.

https://doi.org/10.1182/blood-2019-130900

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Mattia Novo, Grzegorz Nowakowski, MD, Ivana Micallef, MD, Rebecca L. King, MD, Robert Spinner, MD, Kay M. Ristow, BS, Thomas M. Habermann, MD, Patrick Johnston, MD PhD

Blood (2019) 134 (Supplement_1): 4129.

https://doi.org/10.1182/blood-2019-131378

Published: 2019

Journal Articles

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Blood (2019) 134 (Supplement_1): 4028.

https://doi.org/10.1182/blood-2019-130223

Published: 2019

Journal Articles

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Blood (2019) 134 (Supplement_1): 90.

https://doi.org/10.1182/blood-2019-129383

Published: 2019

Journal Articles

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Deokki Eom, BS, Jae Hun Jung, Eun Kyung KIM, PhD, Wolyoung Kim, Qingri Li, Jaehyun Jung, Sohee Im, Yong Dae Shin, Hyaejung Hyun, Joon Seok Park

Blood (2019) 134 (Supplement_1): 4426.

https://doi.org/10.1182/blood-2019-126839

Published: 2019

Journal Articles

A Phase II Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers

Shuo You, MD, Andrew Crouch, Ugochi Olivia Ogu, MD, Clemencia Solorzano, PharmD, Gracy Sebastian, NP, Markenya Mirander, Giacomo Vinces, D.O., Gregory J Kato, MD, Caterina P. Minniti, MD

Blood (2019) 134 (Supplement_1): 2292.

https://doi.org/10.1182/blood-2019-124440

Published: 2019

Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD

Blood (2019) 134 (Supplement_1): 2550.

https://doi.org/10.1182/blood-2019-128626

Published: 2019

Journal Articles

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MDMSc, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro N. Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2637.

https://doi.org/10.1182/blood-2019-127803

Published: 2019

Journal Articles

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Tomasz Zal, PhD, Mateusz Rytelewski, PhD, Rodrigo Jacamo, PhD, Malgorzata Anna Zal, MSc, Meenakshi Shanmugasundaram, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2674.

https://doi.org/10.1182/blood-2019-131945

Published: 2019

Journal Articles

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Rafael Heinz Montoya, Naval G. Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2556.

https://doi.org/10.1182/blood-2019-126950

Published: 2019

Journal Articles

Determinants of Outcomes of FLT3 mut Acute Myeloid Leukemia with First Salvage Therapy

Abhishek Maiti, MBBS, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Srdan Verstovsek, MD PhD, Michael Andreeff, MD PhD, Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MDMSc, Sherry A. Pierce, BSN, BA, Lian-Chun Xiao, Xuelin Huang, PhD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2641.

https://doi.org/10.1182/blood-2019-129621

Published: 2019

Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2019) 134 (Supplement_1): 2642.

https://doi.org/10.1182/blood-2019-129137

Published: 2019

Journal Articles

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Ran Zhao, BS, Sarah Zarabi, MD, Takenobu Nii, PhD, Ondrej Halgas, PhD, Yulia Jitkova, PhD, Vivian Ruvolo, Lauren Heese, Yuki Nishida, MD PhD, Gautam M. Borthakur, MD, Kensuke Kojima, MD PhD, Martin Stogniew, Wolfgang Oster, MD, Emil Pai, PhD, Eric Davis, MD, Hagop M. Kantarjian, MD, Aaron D Schimmer, MD PhD, Michael Andreeff, MD PhD, Jo Ishizawa, MD PhD

Blood (2019) 134 (Supplement_1): 2562.

https://doi.org/10.1182/blood-2019-127101

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I manage acquired pure red cell aplasia in adults

Rare disease + lots of sequencing = mechanism?

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

A Phase II Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Determinants of Outcomes of FLT3 mut Acute Myeloid Leukemia with First Salvage Therapy

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only